DK1529062T3 - Therapeutisk anvendelse af kremen 1 og 2, inhibitorer af den kanoniske WNT-signaltransduktionskaskade - Google Patents
Therapeutisk anvendelse af kremen 1 og 2, inhibitorer af den kanoniske WNT-signaltransduktionskaskadeInfo
- Publication number
- DK1529062T3 DK1529062T3 DK03746281.9T DK03746281T DK1529062T3 DK 1529062 T3 DK1529062 T3 DK 1529062T3 DK 03746281 T DK03746281 T DK 03746281T DK 1529062 T3 DK1529062 T3 DK 1529062T3
- Authority
- DK
- Denmark
- Prior art keywords
- kremen
- creams
- inhibitors
- signal transduction
- therapeutic use
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- General Physics & Mathematics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02008650A EP1355152B1 (en) | 2002-04-17 | 2002-04-17 | Method for identifying a compound for modulating the wnt signal cascade. |
PCT/EP2003/003277 WO2003087818A2 (en) | 2002-04-17 | 2003-03-28 | Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signaltransduction |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1529062T3 true DK1529062T3 (da) | 2011-02-28 |
Family
ID=28459480
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02008650.0T DK1355152T3 (da) | 2002-04-17 | 2002-04-17 | Fremgangsmåde til at identificere en forbindelse til modulering af wnt-signalkaskaden |
DK03746281.9T DK1529062T3 (da) | 2002-04-17 | 2003-03-28 | Therapeutisk anvendelse af kremen 1 og 2, inhibitorer af den kanoniske WNT-signaltransduktionskaskade |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02008650.0T DK1355152T3 (da) | 2002-04-17 | 2002-04-17 | Fremgangsmåde til at identificere en forbindelse til modulering af wnt-signalkaskaden |
Country Status (10)
Country | Link |
---|---|
US (4) | US20050244826A1 (da) |
EP (3) | EP1355152B1 (da) |
JP (2) | JP2005523005A (da) |
AT (2) | ATE459880T1 (da) |
CA (1) | CA2482634C (da) |
DE (2) | DE60235524D1 (da) |
DK (2) | DK1355152T3 (da) |
ES (2) | ES2342152T3 (da) |
IL (3) | IL164276A0 (da) |
WO (1) | WO2003087818A2 (da) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005026720A1 (en) * | 2003-09-04 | 2005-03-24 | Parivid Llc | Methods and apparatus for characterizing polymeric mixtures |
US9046537B2 (en) | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
US8367822B2 (en) * | 2003-09-22 | 2013-02-05 | Enzo Therapeutics, Inc. | Compositions and methods for bone formation and remodeling |
WO2005049640A2 (en) * | 2003-11-17 | 2005-06-02 | Merck & Co., Inc. | Rhesus monkey dickkopf-1, nucleotides encoding same, and uses thereof |
US9052324B2 (en) | 2004-05-19 | 2015-06-09 | Enzo Biochem, Inc. | Compounds and assays for controlling Wnt activity |
JP5419362B2 (ja) * | 2008-02-18 | 2014-02-19 | 公益財団法人ヒューマンサイエンス振興財団 | 活性型cd4陽性t細胞の検査方法 |
WO2018107109A1 (en) * | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Novel anti-kremen2 antibodies and methods of use |
EP3996745A4 (en) * | 2019-07-10 | 2023-04-12 | Yale University | COMPOSITIONS AND METHODS OF USE OF HUMANIZED ANTI-DKK2 ANTIBODY |
CN112592402B (zh) * | 2020-12-02 | 2022-04-26 | 杭州奕安济世生物药业有限公司 | 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ATE199054T1 (de) | 1990-12-06 | 2001-02-15 | Affymetrix Inc A Delaware Corp | Verbindungen und ihre verwendung in einer binären synthesestrategie |
US5322933A (en) | 1992-05-07 | 1994-06-21 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Crystal structure of TGF-β-2 |
ATE301201T1 (de) | 1993-06-07 | 2005-08-15 | Vical Inc | Für die gentherapie verwendbare plasmide |
US6057119A (en) | 1994-06-17 | 2000-05-02 | Vertex Pharmaceuticals, Incorporated | Crystal structure and mutants of interleukin-1β converting enzyme |
WO1997000957A1 (en) | 1995-06-23 | 1997-01-09 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
EP1019043A4 (en) * | 1996-05-07 | 2003-07-30 | Univ Pennsylvania | GLYCOGENE SYNTHETASE KINASE-3 INHIBITORS AND METHODS OF IDENTIFYING AND USING THOSE INHIBITORS |
JP2001504328A (ja) | 1996-10-31 | 2001-04-03 | スミスクライン・ビーチャム・コーポレイション | 医薬上使用される化合物と結合するrna標的モチーフの特徴付けおよび選択の方法 |
US6107473A (en) * | 1997-10-01 | 2000-08-22 | Smithkline Beecham Corporation | Kringle-related clone HTHBZ47 |
US7033780B1 (en) * | 1999-06-14 | 2006-04-25 | Millennium Pharmaceuticals, Inc. | Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein |
EP1130094A3 (en) * | 1999-07-08 | 2001-11-21 | Helix Research Institute | Primers for synthesizing full length cDNA clones and their use |
EP1074617A3 (en) * | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
WO2001034621A1 (en) * | 1999-11-12 | 2001-05-17 | Human Genome Sciences, Inc. | Kringle domain-containing polynucleotides, polypeptides, and antibodies |
US20010036643A1 (en) * | 1999-12-06 | 2001-11-01 | Holloway James L. | Educational kit and method using tumor necrosis factor-stimulated gene and protein |
WO2002002603A2 (en) * | 2000-06-30 | 2002-01-10 | Incyte Genomics, Inc. | Protein modification and maintenance molecules |
JP2005509402A (ja) | 2001-02-16 | 2005-04-14 | ジェネンテック・インコーポレーテッド | Dkk−1又はそのアンタゴニストに関連する治療 |
EP1395285A4 (en) | 2001-05-17 | 2005-06-01 | Genome Therapeutics Corp | REAGENTS AND METHODS FOR MODULATING INDUCED DKK INTERACTIONS |
-
2002
- 2002-04-17 DE DE60235524T patent/DE60235524D1/de not_active Expired - Lifetime
- 2002-04-17 EP EP02008650A patent/EP1355152B1/en not_active Expired - Lifetime
- 2002-04-17 ES ES02008650T patent/ES2342152T3/es not_active Expired - Lifetime
- 2002-04-17 DK DK02008650.0T patent/DK1355152T3/da active
- 2002-04-17 AT AT02008650T patent/ATE459880T1/de active
-
2003
- 2003-03-28 DE DE60335547T patent/DE60335547D1/de not_active Expired - Lifetime
- 2003-03-28 US US10/509,464 patent/US20050244826A1/en not_active Abandoned
- 2003-03-28 DK DK03746281.9T patent/DK1529062T3/da active
- 2003-03-28 ES ES03746281T patent/ES2356438T3/es not_active Expired - Lifetime
- 2003-03-28 CA CA2482634A patent/CA2482634C/en not_active Expired - Fee Related
- 2003-03-28 AT AT03746281T patent/ATE493436T1/de active
- 2003-03-28 WO PCT/EP2003/003277 patent/WO2003087818A2/en active Application Filing
- 2003-03-28 EP EP03746281A patent/EP1529062B1/en not_active Expired - Lifetime
- 2003-03-28 JP JP2003584712A patent/JP2005523005A/ja active Pending
- 2003-03-28 EP EP10004497A patent/EP2218735A1/en not_active Withdrawn
- 2003-03-28 IL IL16427603A patent/IL164276A0/xx active IP Right Grant
-
2004
- 2004-09-26 IL IL164276A patent/IL164276A/en not_active IP Right Cessation
-
2008
- 2008-10-10 US US12/287,729 patent/US7947462B2/en not_active Expired - Fee Related
- 2008-12-18 JP JP2008322976A patent/JP5068734B2/ja not_active Expired - Fee Related
-
2010
- 2010-09-16 IL IL208179A patent/IL208179A/en not_active IP Right Cessation
-
2011
- 2011-04-05 US US13/066,024 patent/US8227200B2/en not_active Expired - Fee Related
-
2012
- 2012-06-22 US US13/530,787 patent/US20130302339A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DK1355152T3 (da) | 2010-06-14 |
IL164276A (en) | 2011-10-31 |
ES2356438T3 (es) | 2011-04-08 |
IL164276A0 (en) | 2005-12-18 |
EP1355152B1 (en) | 2010-03-03 |
EP2218735A1 (en) | 2010-08-18 |
IL208179A (en) | 2012-03-29 |
WO2003087818A2 (en) | 2003-10-23 |
JP2005523005A (ja) | 2005-08-04 |
JP2009145352A (ja) | 2009-07-02 |
US20050244826A1 (en) | 2005-11-03 |
ATE493436T1 (de) | 2011-01-15 |
AU2003226745A1 (en) | 2003-10-27 |
US8227200B2 (en) | 2012-07-24 |
DE60335547D1 (de) | 2011-02-10 |
DE60235524D1 (de) | 2010-04-15 |
ES2342152T3 (es) | 2010-07-02 |
WO2003087818A3 (en) | 2004-02-05 |
JP5068734B2 (ja) | 2012-11-07 |
US20090192109A1 (en) | 2009-07-30 |
US20110287420A1 (en) | 2011-11-24 |
ATE459880T1 (de) | 2010-03-15 |
EP1529062B1 (en) | 2010-12-29 |
CA2482634A1 (en) | 2003-10-23 |
CA2482634C (en) | 2014-06-10 |
IL208179A0 (en) | 2010-12-30 |
US7947462B2 (en) | 2011-05-24 |
EP1529062A2 (en) | 2005-05-11 |
US20130302339A1 (en) | 2013-11-14 |
EP1355152A1 (en) | 2003-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL208179A0 (en) | Nuckeic acud nolecules encoding human kremen 1 and human kremen 2 and diagnostic and pharmaceutical compositions based thereon | |
DK1673475T3 (da) | Sammensætninger til diagnose og terapi af sygdomme, som er forbundet med aberrant ekspression af futriner (R-Spondiner) og/eller Wnt | |
BRPI0410746A (pt) | compostos e composições imunossupressoras | |
ES2401237T3 (es) | Uso del oleocantal principal irritante en aceite de oliva, así como compuestos estructural y funcionalmente similares | |
NO20055837L (no) | Immunsupprimerende forbindelser og sammensetninger | |
HUP0202655A2 (hu) | N-[(amino-imino-metil)- és N-[(amino-metil)-fenil]-propil-amid származékok | |
ATE484494T1 (de) | Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen | |
BR0313290A (pt) | Derivado de pirazol, composição medicinal contendo o mesmo, uso medicinal dele, e intermediário para a sua produção | |
GB0222495D0 (en) | Compounds | |
NO20035496D0 (no) | Substituerte sulfonamidforbindelser, fremgangsmåte for deres anvendelse sommedikament til behandling av CNS-forstyrrelser, overvekt og typeII-diabetes | |
BRPI0409910A (pt) | métodos para o tratamento de doenças relacionadas com interleucina-6 | |
NO20065717L (no) | Substituerte N-arylbenzamider og beslektede forbindelser for behandling av amyloidsykdommer og synukleinopatier. | |
HUP0103376A2 (hu) | Új 3-aril-2-hidroxi-propinsav-származék, ezt tartalmazó gyógyszerkészítmények, eljárás az előállításukra és alkalmazásuk | |
HUP0300057A2 (en) | Glucopyranosyloxy benzylbenzene derivatives, pharmaceutical compositions containing the same and intermediates for the preparation of the derivatives | |
EP1878725A3 (en) | Pyrimidine derivatives and their use as CB2 modulators | |
TNSN07361A1 (en) | 3,4-substituted pyrrolidine derivatives for the treatment of hypertension | |
MX2007011009A (es) | Compuestos de piperidina 3,4,5-substituidos. | |
BR0314302A (pt) | Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf) | |
NO20064982L (no) | 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav | |
UA83691C2 (ru) | Применение замещенных 2-аминотетралинов для упреждающего лечения болезни паркинсона | |
DK1727817T3 (da) | Azabicyclooctan-3-onderivativer og anvendelse heraf | |
EA200701856A1 (ru) | Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении | |
HUP0202692A2 (hu) | Interleukin-5 inhibitor hatású 6-azauracil-származékok, ezeket tartalmazó gyógyszerkészítmények és intermedierjeik | |
EP1812007A4 (en) | PYRIDAZINE COMPOUNDS AND METHODS | |
DE60207612D1 (de) | Verbindungen zur bilddarstellung der alzheimer-krankenheit |